FrancophonIA/ELRC3.0 huggingface dataset:
English: Fendrix must not be used in people who are hypersensitive (allergic) to the active substance or any of the other ingredients or have had an allergic reaction after being given a hepatitis B vaccine.
Slovenian: Cepiva Fendrix ne smejo uporabljati osebe, ki so preobčutljive za (alergične na) zdravilno učinkovino ali katero koli drugo sestavino zdravila ali pri katerih so se pojavile alergijske reakcije po tem, ko so prejeli cepivo proti hepatitisu B. Cepivo Fendrix se ne sme dajati bolnikom s hudo in nenadno visoko telesno temperaturo.
English: Fendrix was compared with a double dose of Engerix B (another hepatitis B vaccine).
Slovenian: Cepivo Fendrix so primerjali s cepivom Engerix B (drugim cepivom proti virusu hepatitisa B), ki so ga uporabljali v dvojnem odmerku.
English: How has Fendrix been studied?
Slovenian: Kako je bilo zdravilo Fendrix raziskano?
English: How does Fendrix work?
Slovenian: Kako zdravilo Fendrix deluje?
English: What is Fendrix?
Slovenian: Kaj je zdravilo Fendrix?
English: What is Fendrix used for?
Slovenian: Za kaj se zdravilo Fendrix uporablja?
English: How is Fendrix used?
Slovenian: Kako se zdravilo Fendrix uporablja?
English: When a patient is given the vaccine, the immune system recognises the surface antigens as ‘foreign' and makes antibodies against them.
Slovenian: Cepivo Fendrix vsebuje majhno količino „površinskega antigena“ (beljakovine iz površine) virusa hepatitisa B. Ko oseba prejme cepivo, imunski sistem prepozna površinske beljakovine kot „tujke“ in začne proti njim tvoriti protitelesa.
English: (Invented) name Strength Pharmaceutical Form Route of Administration
Slovenian: (Izmišljeno) ime Jakost
English: Higher doses were no more effective than this dose.
Slovenian: Višji odmerki niso bili učinkovitejši od tega odmerka.
English: Doses of FSH are adjusted according to the response, and treatment may continue for up to five weeks.
Slovenian: Odmerki FSH se prilagajajo glede na odziv, pri čemer lahko zdravljenje traja do pet tednov.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Luveris to Merck Serono Europe Limited on 29 November 2000.
Slovenian: Evropska komisija je dovoljenje za promet z zdravilom Luveris, veljavno po vsej Evropski uniji, odobrila družbi Merck Serono Europe Limited dne 29. novembra 2000.
English: If the powder and solvent are used, they should be mixed together just before use.
Slovenian: Če se uporabljata prašek in vehikel, ju je treba zmešati tik pred uporabo.
English: Because the number of patients with this condition is low, Luveris was not compared with any other medicines.
Slovenian: Ker je bilo število bolnic s tem stanjem majhno, zdravila Luveris niso primerjali z nobenim drugim zdravilom.
English: The patient's response to treatment is monitored to check how the egg development in the ovary is progressing.
Slovenian: Odziv bolnice na zdravljenje se spremlja, da bi preverili, kako napreduje razvoj jajčec v jajčniku.
English: The full EPAR for Luveris can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Slovenian: Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Luveris je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: Lutropin alfa is produced by a method known as ‘recombinant DNA technology': it is made by a cell that has received a gene (DNA), which makes it able to produce human LH.
Slovenian: Lutropin alfa je izdelan z metodo, imenovano „tehnologija rekombinantne DNK“: izdela ga celica, ki je prejela gen (DNK), s katerim lahko tvori humani LH.
English: The patient may carry out the injection herself if she is well-motivated, has been adequately trained and has access to expert advice.
Slovenian: Bolnica lahko injiciranje izvede sama, če je dovolj motivirana, če je bila za to ustrezno usposobljena ali če ima možnost posvetovanja s strokovnjakom.
English: In the main study, 67% of the women who received the approved dose of Luveris (75 International Units) together with FSH produced functional follicles (6 out of 9).
Slovenian: V glavni študiji so pri 67 % žensk, ki so prejele odobreni odmerek zdravila Luveris (75 internacionalnih enot) v kombinaciji s FSH, nastali funkcionalni folikli (6 od 9).
English: The main measure of effectiveness was the number of women who produced functional follicles (eggs in the ovaries that are ready for release).
Slovenian: Glavno merilo učinkovitosti je bilo število žensk, pri katerih so nastali funkcionalni folikli (jajčeca v jajčnikih, ki so pripravljena na ovulacijo).
English: The resulting solution can be mixed with FSH in the same syringe.
Slovenian: Nastalo raztopino je mogoče zmešati s FSH v isti brizgi.
English: FSH, which is used together with Luveris, also stimulates ovulation.
Slovenian: FSH, ki se uporablja skupaj z zdravilom Luveris, prav tako spodbuja ovulacijo.
English: EPAR summary for the public lutropin alfa
Slovenian: Povzetek EPAR za javnost lutropin alfa
English: For more information about treatment with Luveris, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Slovenian: Za več informacij o zdravljenju z zdravilom Luveris preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte s svojim zdravnikom ali farmacevtom.
English: In the body, LH causes the release of eggs (ovulation) during the menstrual cycle.
Slovenian: LH v telesu povzroči sprostitev jajčec (ovulacijo) med menstrualnim ciklom.
English: Other information about Luveris
Slovenian: Druge informacije o zdravilu Luveris
English: The CHMP decided that Luveris's benefits are greater than its risks and recommended that it be given marketing authorisation.
Slovenian: CHMP je zaključil, da so koristi zdravila Luveris večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
English: The most common side effects with Luveris (seen in between 1 and 10 patients in 100) are reactions at the injection site (pain, redness, bruising or swelling), headache,, nausea (feeling sick), vomiting, diarrhoea, abdominal pain and discomfort, pelvic (lower abdominal) pain, mild to moderate ovarian hyperstimulation syndrome, ovarian cyst (development of a fluid-filled cavity in the ovary) and breast pain.
Slovenian: Najpogostejši neželeni učinki zdravila Luveris (opaženi pri 1 do 10 bolnicah od 100) so reakcije na mestu injiciranja (bolečina, rdečina, modrice, ali otekanje), glavobol, navzeja (slabost), bruhanje, driska, bolečina in neprijeten občutek v trebuhu, bolečine v medenici, blag do zmeren sindrom ovarijske hiperstimulacije, ovarijska cista in bolečine v dojkah.
English: Treatment with Luveris should be carried out by a doctor who has experience in the treatment of fertility problems.
Slovenian: Zdravljenje z zdravilom Luveris mora izvajati zdravnik z izkušnjami pri zdravljenju težav s plodnostjo.
English: What benefit has Luveris shown during the studies?
Slovenian: Kakšne koristi je zdravilo Luveris izkazalo med študijami?
English: It must also not be used when there is enlargement of the ovaries or cysts that are not related to polycystic ovarian disease and are of unknown origin, or unexplained bleeding from the vagina.
Slovenian: Ne sme se uporabljati ob povečanju jajčnikov ali prisotnosti cist, ki niso povezane s policističnim obolenjem jajčnikov in so neznanega izvora, ali nepojasnjenem krvavenju iz nožnice.
English: It is used with follicle stimulating hormone (FSH) to stimulate the development of eggs in the ovaries of adult women who have severe deficiency (very low levels) of luteinising hormone (LH) and FSH.
Slovenian: Uporablja se s folikle stimulirajočim hormonom (FSH) za spodbujanje nastajanja jajčec v jajčnikih pri odraslih ženskah s hudim pomanjkanjem (zelo nizko ravnjo) luteinizirajočega hormona (LH) in FSH.
English: This is a summary of the European public assessment report (EPAR) for Luveris.
Slovenian: Ta dokument je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Luveris.
English: Luveris, given together with FSH, has been studied in one main study involving 38 women with severe LH and FSH deficiency.
Slovenian: Zdravilo Luveris, ki so ga bolniki jemali skupaj s FSH, je bilo raziskano v eni glavni študiji, v katero je bilo vključenih 38 žensk s hudim pomanjkanjem LH in FSH.
English: Luveris is given once a day together with FSH.
Slovenian: Zdravilo Luveris se daje enkrat dnevno skupaj s FSH.
English: Luveris should not be used in people who may be hypersensitive (allergic) to LH, FSH or any of the other ingredients.
Slovenian: Zdravila Luveris ne smejo uporabljati osebe, ki utegnejo biti preobčutljive za (alergične na) LH, FSH ali katero koli drugo sestavino zdravila.
English: Luveris is given by injection under the skin.
Slovenian: Zdravilo Luveris se injicira pod kožo.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Luveris.
Slovenian: Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil zdravilo Luveris, na podlagi česar je oblikoval mnenje za odobritev dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
English: What is the risk associated with Luveris?
Slovenian: Kakšna tveganja so povezana z zdravilom Luveris?
English: Ovarian hyperstimulation syndrome occurs when the ovaries over respond to treatment, especially when medicines to trigger ovulation have been used, and can cause nausea, weight gain and diarrhoea.
Slovenian: Sindrom ovarijske hiperstimulacije nastopi, kadar je odziv jajčnikov na zdravljenje prevelik, zlasti če so uporabljena zdravila za sprožitev ovulacije, in lahko povzroči navzejo, povečanje telesne mase in drisko.
English: The active substance in Luveris, lutropin alfa, is a copy of the natural hormone LH.
Slovenian: Učinkovina zdravila Luveris, lutropin alfa, je kopija naravnega luteinizirajočega hormona (LH).
English: It is available as a powder and solvent that are made up into a solution for injection, and as a solution for injection in a pre-filled pen.
Slovenian: Na voljo je v obliki praška in vehikla, ki se zmešata v raztopino za injiciranje, ter v obliki raztopine za injiciranje v napolnjenem peresniku.
English: Luveris is a medicine that contains the active substance lutropin alfa.
Slovenian: Luveris je zdravilo, ki vsebuje zdravilno učinkovino lutropin alfa.
English: Why has Luveris been approved?
Slovenian: Zakaj je bilo zdravilo Luveris odobreno?
English: For the full list of all side effects reported with Luveris, see the package leaflet.
Slovenian: Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Luveris, glejte navodilo za uporabo.
English: It must not be used in women who have tumours of the pituitary gland, hypothalamus (a region of the brain), breast, womb or ovary.
Slovenian: Ne smejo ga uporabljati bolnice s tumorji hipofize, hipotalamusa, dojk, maternice ali jajčnikov.
English: What is Luveris?
Slovenian: Kaj je zdravilo Luveris?
English: What is Luveris used for?
Slovenian: Za kaj se zdravilo Luveris uporablja?
English: How has Luveris been studied?
Slovenian: Kako je bilo zdravilo Luveris raziskano?
English: How is Luveris used?
Slovenian: Kako se zdravilo Luveris uporablja?
English: Luveris is a fertility treatment.
Slovenian: Zdravilo Luveris je namenjeno za zdravljenje težav s plodnostjo.
English: How does Luveris work?
Slovenian: Kako zdravilo Luveris deluje?
English: This overview was last updated in 04-2019.
Slovenian: Pregled je bil nazadnje posodobljen 04-2019.
English: Adempas is available as tablets (0.5, 1, 1.5, 2 and 2.5 mg).
Slovenian: Na voljo je v obliki tablet (0,5, 1, 1,5, 2 in 2,5 mg).
English: It also noted that no other medicines have been authorised for CTEPH.
Slovenian: Izpostavila je tudi, da za CTEPH ni odobreno nobeno drugo zdravilo.
English: The usual recommended starting dose is 1 mg three times a day (approximately 6 to 8 hours apart) for two weeks.
Slovenian: Običajni priporočeni začetni odmerek je 1 mg trikrat na dan (približno vsakih šest do osem ur) v obdobju dveh tednov.
English: The dose is then increased every two weeks until the appropriate dose for the individual patient is established.
Slovenian: Odmerek se nato vsaka dva tedna povečuje do odmerka, ki je primeren za posameznega bolnika.
English: What measures are being taken to ensure the safe and effective use of Adempas?
Slovenian: Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Adempas?
English: Further information on the orphan designation can be found here: ema.europa.eu/en/medicines/human/orphan-designations/eu307518.
Slovenian: Nadaljnje informacije glede določitve zdravila sirote lahko najdete tukaj: ema.europa.eu/en/medicines/human/orphan-designations/eu307518.
English: The Agency therefore decided that Adempas's benefits are greater than its risks and that it can be authorised for use in the EU.
Slovenian: Agencija je zato zaključila, da so koristi zdravila Adempas večje od z njim povezanih tveganj in da se lahko odobri za uporabo v EU.
English: Adempas received a marketing authorisation valid throughout the European Union on 27 March 2014.
Slovenian: Za zdravilo Adempas je bilo 27. marca 2014 izdano dovoljenje za promet, veljavno po vsej EU.
English: An overview of Adempas and why it is authorised in the EU
Slovenian: Pregled zdravila Adempas in zakaj je odobreno v EU
English: The ‘class' reflects the seriousness of the disease: ‘class II' involves slight limitation of physical activity while ‘class III' involves marked limitation of physical activity.
Slovenian: Razred opredeljuje resnost bolezni: „razred II“ vključuje rahlo omejeno telesno zmogljivost, „razred III“ pa izrazito omejeno telesno zmogljivost.
English: Other information about Adempas
Slovenian: Druge informacije o zdravilu Adempas
English: As for all medicines, data on the use of Adempas are continuously monitored.
Slovenian: Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila Adempas stalno spremljajo.
English: What benefits of Adempas have been shown in studies?
Slovenian: Kakšne koristi zdravila Adempas so se pokazale v študijah?
English: Further information on Adempas can be found on the Agency's website: ema.europa.eu/en/medicines/human/EPAR/adempas.
Slovenian: Nadaljnje informacije o zdravilu Adempas so na voljo na spletni strani agencije: ema.europa.eu/en/medicines/human/EPAR/adempas.
English: For patients unable to swallow whole tablets, the tablets may be crushed and mixed with water or soft food such as apple sauce.
Slovenian: Če bolniki ne morejo pogoltniti celih tablet, se lahko tablete zdrobijo in zmešajo z vodo ali mehko hrano, na primer jabolčno čežano.
English: • The medicine was also compared with placebo in another main study in 445 patients with PAH.
Slovenian: • Zdravilo so s placebom primerjali še v eni glavni študiji s 445 bolniki s PAH.
English: This helps to lower the blood pressure in the lungs and improve symptoms of CTEPH and PAH.
Slovenian: To pomaga pri znižanju krvnega tlaka v pljučih in izboljšanju simptomov CTEPH in PAH.
English: Side effects reported with Adempas are carefully evaluated and any necessary action taken to protect patients.
Slovenian: Neželeni učinki, o katerih so poročali pri zdravilu Adempas, se skrbno ovrednotijo in po potrebi se sprejmejo ukrepi za zaščito bolnikov.
English: What is Adempas and what is it used for?
Slovenian: Kaj je zdravilo Adempas in za kaj se uporablja?
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Adempas have been included in the summary of product characteristics and the package leaflet.
Slovenian: Priporočila in previdnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Adempas upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
English: What are the risks associated with Adempas?
Slovenian: Kakšna tveganja so povezana z zdravilom Adempas?
English: Regarding safety it considered that side effects of concern, including haemoptysis and pulmonary haemorrhage, have been adequately reflected in the product information and risk management plan.
Slovenian: V zvezi z varnostjo je agencija menila, da so zadevni neželeni učinki, kot so hemoptiza in pljučne krvavitve, ustrezno obravnavani v informacijah o zdravilu in načrtu obvladovanja tveganj.
English: For more information about using Adempas, see the package leaflet or contact your doctor or pharmacist.
Slovenian: Za več informacij glede uporabe zdravila Adempas glejte navodilo za uporabo ali se posvetujte z zdravnikom ali farmacevtom.
English: Why is Adempas approved?
Slovenian: Zakaj je bilo zdravilo Adempas odobreno?
English: As a result, the amount of oxygen that can get into the blood in the lungs is reduced, making physical activity more difficult.
Slovenian: Zaradi tega se zmanjša količina kisika, ki prehaja v kri v pljučih, kar oteži izvajanje telesnih dejavnosti.
English: CTEPH and PAH are rare, and Adempas was designated an ‘orphan medicine' (a medicine used in rare diseases) on 20 December 2007.
Slovenian: Bolezni CTEPH in PAH sta redki, zato je bilo zdravilo Adempas 20. decembra 2007 določeno kot „zdravilo sirota“ (zdravilo za zdravljenje redkih bolezni).
English: Adempas can only be obtained with a prescription and treatment should only be started and monitored by a doctor who has experience in the treatment of CTEPH or PAH.
Slovenian: Predpisovanje in izdaja zdravila Adempas je le na recept, zdravljenje z njim pa lahko predpiše in spremlja samo zdravnik, ki ima izkušnje z zdravljenjem CTEPH ali PAH.
English: The most common side effects with Adempas (which may affect more than 1 in 10 people) are headache, dizziness, dyspepsia (heartburn), peripheral oedema (swelling, especially of the ankles and feet), nausea (feeling sick), diarrhoea and vomiting.
Slovenian: Najpogostejši neželeni učinki zdravila Adempas (ki se lahko pojavijo pri več kot 1 od 10 bolnikov) so glavobol, omotica, dispepsija (zgaga), periferni edem (otekanje, zlasti stopal in gležnjev), navzeja (siljenje na bruhanje), driska in bruhanje.
English: Adempas is a medicine that is used to increase the ability to carry out physical activity in adults with the following forms of pulmonary hypertension (high blood pressure in the blood vessels of the lungs):
Slovenian: Zdravilo Adempas se uporablja za povečanje zmožnosti za izvajanje telesnih dejavnosti pri odraslih z naslednjimi oblikami pljučne hipertenzije (visokega krvnega tlaka v krvnih žilah v pljučih):
English: Adempas is used in patients with functional class II to III CTEPH or PAH.
Slovenian: Zdravilo Adempas se uporablja pri bolnikih s CTEPH ali PAH funkcionalnega razreda II ali III.
English: Adempas can be used on its own or in combination with other medicines for PAH called ‘endothelin receptor antagonists'.
Slovenian: Zdravilo Adempas se lahko uporablja samostojno ali v kombinaciji z drugimi zdravili za zdravljenje pljučne arterijske hipertenzije, imenovanimi „antagonisti endotelinskih receptorjev“.
English: It must also not be used together with medicines called ‘PDE 5 inhibitors' (a class of medicines used for PAH or erectile dysfunction) or with nitrates or nitric oxide donors (often used to treat high blood pressure, chest pain and heart disease, or as recreational drugs).
Slovenian: Prav tako se ne sme uporabljati skupaj z zdravili, imenovanimi „zaviralci PDE5“ (skupina zdravil, ki se uporabljajo za PAH ali erektilno disfunkcijo), in z nitrati ali donorji dušikovega oksida (ti se pogosto uporabljajo za zdravljenje visokega krvnega tlaka,
English: • Adempas was compared with placebo (a dummy treatment) in one main study in 262 patients with CTEPH who could not be operated, or in whom CTEPH remained or returned after surgery.
Slovenian: • Zdravilo Adempas so primerjali s placebom (zdravilom brez učinkovine) v eni glavni študiji, v kateri je sodelovalo 262 bolnikov s CTEPH, ki jih ni bilo mogoče operirati, in bolnikov s CTEPH, pri katerih bolezen po operaciji ni izginila ali se je ponovno pojavila.
English: The European Medicines Agency considered that Adempas led to significant improvements in exercise capacity in patients with CTEPH or PAH.
Slovenian: Evropska agencija za zdravila je menila, da je zdravilo Adempas pomembno izboljšalo telesno zmogljivost bolnikov s CTEPH ali PAH.
English: Adempas must not be used in patients with severely reduced liver function, with systolic blood pressure (blood pressure when the heart is contracting) below 95 mmHg before starting treatment, or during pregnancy.
Slovenian: Zdravilo Adempas se ne sme uporabljati pri bolnikih z močno zmanjšanim delovanjem jeter, pri bolnikih, ki imajo pred začetkom zdravljenja sistolični krvni tlak (krvni tlak, ki nastane, ko se srce skrči) nižji od 95 mmHg, in pri nosečnicah.
English: Adempas has been shown to be effective at improving the distance patients with CTEPH or PAH could walk in 6 minutes (a way of measuring exercise capacity):
Slovenian: Zdravilo Adempas se je izkazalo za učinkovito pri izboljšanju razdalje, ki so jo bolniki s CTEPH ali PAH lahko prehodili v šestih minutah (metoda merjenja telesne zmogljivosti).
English: Adempas contains the active substance riociguat.
Slovenian: Zdravilo Adempas vsebuje učinkovino riociguat.
English: This causes high blood pressure in the vessels taking blood from the heart to the lungs and reduces the blood flow to the lungs.
Slovenian: Posledica sta visok krvni tlak v žilah, po katerih teče kri iz srca v pljuča, in zmanjšan pretok krvi v pljuča.
English: CTEPH and PAH are debilitating diseases where there is severe narrowing of the blood vessels of the lungs.
Slovenian: CTEPH in PAH sta izčrpavajoči bolezni, ki povzročita hudo zoženje krvnih žil v pljučih.
English: The active substance in Adempas, riociguat, stimulates an enzyme called ‘soluble guanylate cyclase' in the blood vessels of the lungs, which causes the blood vessels to relax and widen.
Slovenian: Učinkovina v zdravilu Adempas, riociguat, spodbuja encim, imenovan „topna gvanilat-ciklaza“, v krvnih žilah v pljučih, kar jim omogoča sprostitev in razširitev.
English: After 12 weeks, patients treated with Adempas could walk 36 metres further in 6 minutes than patients taking placebo.
Slovenian: Po 12 tednih so lahko bolniki, ki so jih zdravili z zdravilom Adempas, v šestih minutah prehodili 36 metrov več kot bolniki, ki so jemali placebo.
English: Serious side effects include haemoptysis (coughing up blood) and pulmonary haemorrhage (bleeding in the lungs).
Slovenian: Med resnimi neželenimi učinki so hemoptiza (izkašljevanje krvi) in pljučna hemoragija (krvavitev v pljuča).
English: After 16 weeks, patients treated with Adempas could walk on average 46 metres further in 6 minutes than patients taking placebo.
Slovenian: Po 16 tednih so lahko bolniki, ki so jih zdravili z zdravilom Adempas, v šestih minutah v povprečju prehodili 46 metrov več kot bolniki, ki so jemali placebo.
English: Adempas is used to treat patients with CTEPH who cannot be operated on, or in whom CTEPH remains or returns after surgery.
Slovenian: Zdravilo Adempas se uporablja za zdravljenje bolnikov s CTEPH, ki jih ni mogoče operirati, in bolnikov, pri katerih bolezen po operaciji ne izgine ali se ponovno pojavi;
English: • Chronic thromboembolic pulmonary hypertension (CTEPH, where the blood vessels of the lungs are blocked or narrowed with blood clots).
Slovenian: • kronično trombembolično pljučno hipertenzijo (CTEPH, tj. boleznijo, pri kateri so krvne žile v pljučih zamašene ali zožene zaradi krvnih strdkov).
English: How is Adempas used?
Slovenian: Kako se zdravilo Adempas uporablja?
English: Before treatment the patients could walk an average of 363 metres in 6 minutes.
Slovenian: Pred zdravljenjem so bolniki v šestih minutah povprečno lahko prehodili 363 metrov.
English: Before treatment, the patients could walk an average of 347 metres in 6 minutes.
Slovenian: Bolniki so pred zdravljenjem v povprečju lahko prehodili 347 metrov v šestih minutah.